European Medicines Agency begins review of marketing authorisation application for voxelotor for treatment of haemolytic anaemia in sickle cell disease

Voxelotor is a first-in-class inhibitor of haemoglobin polymerisation, the root cause of the sickling and destruction of red blood cells in sickle cell disease. The application is based on data from the Phase III HOPE trial and the Phase II HOPE-KIDS 1 Study.

Source:

Biospace Inc.